Patents Assigned to Amgen Inc.
  • Patent number: 10709845
    Abstract: A rotatable drive mechanism for a drug delivery device may include a lead screw having a distal end, a proximal end, and external threads, a bearing, and a ball screw driver having a threaded aperture wherein the threaded aperture is configured to rotatably engage with the external threads of the lead screw. The mechanism may further include a biasing device disposed between the bearing and the ball screw driver generating an axial drive force, and an activation device configured to release the biasing device and allowing the biasing device to expand from a compressed position to an extended position through which the axial drive force of the biasing device causes the ball screw driver to axially move toward the distal end of the lead screw and rotate the lead screw such that a threaded engagement between the lead screw and the ball screw driver bears the axial drive force.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: July 14, 2020
    Assignee: AMGEN INC.
    Inventor: Steve Sanchez
  • Publication number: 20200216546
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Application
    Filed: January 16, 2020
    Publication date: July 9, 2020
    Applicant: Amgen, Inc.
    Inventors: Shaw-Fen Sylvia HU, Ian Nevin FOLTZ, Chadwick Terence KING, Yang LI, Taruna ARORA
  • Publication number: 20200207747
    Abstract: The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: (insert Formula I structure) wherein variables W, X, Y, R2, R2?, R3, R4, R5, R6, and R7 of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to beta amyloid (A?) plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.
    Type: Application
    Filed: December 13, 2017
    Publication date: July 2, 2020
    Applicant: AMGEN INC.
    Inventors: Jennifer R. ALLEN, Matthew P. BOURBEAU, Ning CHEN, Michael J. FROHN, Paul E. HARRINGTON, Qingyian LIU, Corey REEVES
  • Patent number: 10695492
    Abstract: A drug delivery system is disclosed that includes a drug delivery device having a reservoir and a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient. The drug delivery system may further include one or more sensors coupled to the drug delivery device, a wireless transmitter, and a controller coupled to the one or more sensors and the wireless transmitter. The controller may be configured to use the one or more sensors to determine a condition or an operational state of the drug delivery device, and control the wireless transmitter to wirelessly transmit one or more reports representative of the condition or the operational state of the drug delivery device. A method for use with a drug delivery device is also disclosed.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: June 30, 2020
    Assignee: AMGEN INC.
    Inventors: Adam B. McCullough, Ferry Tamtoro, Huaying Yang, Mark Ka Lai Lee, Desheng Yin, Scott R. Gibson, Donald Busby, Peter V. Shultz, Keith P. Kogler, Jimmie L. Ward, Christopher R. Folk, Steven William Badelt
  • Patent number: 10695506
    Abstract: A drug injection device (10) including a housing (12) for holding a container (20) having a needle (24) for penetrating skin and a plunger (42) for expelling a drug stored in the container. The device includes visual and/or audible indicators for indicating that the correct depth of needle penetration has been achieved and that drug injection/extrusion has been started and/or completed. The device may further include a label (140) for visually confirming the quality of the drug contained therein. Alternatively, a tray (110) may be provided for receiving the drug injection device, which allows the quality of the drug contained therein to be visually confirmed.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: June 30, 2020
    Assignee: AMGEN INC.
    Inventors: Peter V. Shultz, Christopher R. Folk, Sigrid Moeslinger, Masamichi Udagawa, Molly Evans, Lin Gao, Lisa Nugent
  • Publication number: 20200199153
    Abstract: The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): (Formula (I)) wherein variables X, Y, R2, R3, R4, R5, R6, and n of Formula (I) are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A? plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's disease, cognitive deficits, cognitive impairments, and other central nervous system conditions.
    Type: Application
    Filed: December 13, 2017
    Publication date: June 25, 2020
    Applicant: AMGEN INC.
    Inventors: Jennifer R. ALLEN, Matthew P. BOURBEAU, Ning CHEN, Qingyian LIU, Liping H. PETTUS, Aaron C. SIEGMUND
  • Patent number: 10689367
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the structures where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 23, 2020
    Assignee: AMGEN INC.
    Inventors: Yinhong Chen, Alan C. Cheng, Mikkel V. Debenedetto, Paul John Dransfield, James S. Harvey, Jonathan Houze, Aarif Yusuf Khakoo, Su-Jen Lai, Zhihua Ma, Vatee Pattaropong, Gayathri Swaminath, Charles Kreiman, David C. Moebius, Ankit Sharma
  • Publication number: 20200190137
    Abstract: The invention pertains to methods of purifying fusion proteins, in particular TNFR:Fc fusion proteins. Methods disclosed herein can be used to produce highly pure TNFR:Fc fusion proteins (e.g., etanercept) having a biological activity by removing hard to separate product related impurities such as clipped and/or mis-fold/aggregated TNFR:Fc fusion proteins.
    Type: Application
    Filed: December 10, 2019
    Publication date: June 18, 2020
    Applicant: AMGEN INC.
    Inventors: Ashish Sharma, Balakumar Thangaraj
  • Patent number: 10682474
    Abstract: A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. The wall has at least a first tapered region at the first end to define an opening in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula. The reservoir is connected to the second end of the blunt cannula.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: June 16, 2020
    Assignee: AMGEN INC.
    Inventors: Lawrence Ring, Dhairya Mehta, Stephanie Toy, Ferry Tamtoro, Alexander Stuart Cairns, Scott R. Gibson
  • Patent number: 10682336
    Abstract: Methods of treating immune reconstitution inflammatory syndrome (IRIS) in immunodeficient patients, including HIV patients, using PDE4 modulators are described.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: June 16, 2020
    Assignee: AMGEN INC.
    Inventors: Vikram Khetani, Jerome Zeldis
  • Patent number: 10675353
    Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: June 9, 2020
    Assignee: AMGEN INC.
    Inventors: Gary Luehr, Shabbir T. Anik, Ge Peng, Irina Dotsenko, Pasit Phiasivongsa, Dante Romanini
  • Publication number: 20200172614
    Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
    Type: Application
    Filed: September 16, 2019
    Publication date: June 4, 2020
    Applicant: AMGEN INC.
    Inventors: Cen XU, Agnes Eva HAMBURGER
  • Publication number: 20200172947
    Abstract: The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.
    Type: Application
    Filed: February 5, 2020
    Publication date: June 4, 2020
    Applicant: AMGEN INC.
    Inventors: Daniel R. LEISKE, Michael T. TRENTALANGE
  • Publication number: 20200171043
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 4, 2020
    Applicant: AMGEN INC.
    Inventors: Paul E. HARRINGTON, Kate ASHTON, Sean P. BROWN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Yunxiao LI, Jonathan D. LOW, Ana Elena MINATTI, Alexander J. PICKRELL, Markian M. STEC, Joshua TAYGERLY
  • Patent number: 10668154
    Abstract: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: June 2, 2020
    Assignee: Amgen Inc.
    Inventors: Tiansheng Li, Christopher James Sloey
  • Patent number: 10668067
    Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: June 2, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, John R. Butler, Benjamin Charles Milgram, Gwenaella Rescourio, Alessandro Boezio, Brian Andrew Sparling, Daniel La
  • Patent number: 10655156
    Abstract: Methods of modulating the properties of a cell culture expressing a protein of interest are provided. In various embodiments the methods relate to the overexpression of proteins involved in the N-glycosylation pathway.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: May 19, 2020
    Assignee: Amgen Inc.
    Inventors: Shivani Gupta, Sohye Kang
  • Patent number: 10653781
    Abstract: A stable pharmaceutical formulation is provided that comprises a biologically active protein and an excipient selected from carnitine, creatine or creatinine.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: May 19, 2020
    Assignee: AMGEN INC.
    Inventors: Christopher James Sloey, Camille Gleason, Jason Ko, Tiansheng Li
  • Patent number: D886281
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: June 2, 2020
    Assignee: AMGEN INC.
    Inventors: Margaux Frances Boyaval, Sigrid Moeslinger, Masamichi Udagawa
  • Patent number: D886282
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: June 2, 2020
    Assignee: AMGEN INC.
    Inventors: Brian Stonecipher, Ferry Tamtoro, Ryan Jerome Ramos, Sigrid Moeslinger, Masamichi Udagawa, Gail Devan Hunter, Laurie Martin Burns